I

Immutep Limited
D

IMMP

1.85000
USD
-0.12
(-6.09%)
Market Closed
Volume
3,052
EPS
-17
Div Yield
-
P/E
-7
Market Cap
268,733,274
News

Title: Immutep Limited

Sector: Healthcare
Industry: Biotechnology
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.